Please login to the form below

Not currently logged in
Email:
Password:

Xiidra

This page shows the latest Xiidra news and features for those working in and with pharma, biotech and healthcare.

Takeda sells blockbuster-in-waiting Xiirda to Novartis for $5.3bn

Takeda sells blockbuster-in-waiting Xiirda to Novartis for $5.3bn

Xiidra was first launched in the US in 2016, and generated sales of around $400m last year. ... Xiidra, with its unique dual benefits, is an example of the type of innovative advances we invest in for the benefit of patients," said Paul Hudson, CEO

Latest news

  • Shire files dry eye drug lifitegrast in Europe Shire files dry eye drug lifitegrast in Europe

    Analysts predict Xiidra could become a $1bn product. Shire is awaiting the go-ahead of lifitegrast in the EU, seeking approval for the would-be dry eye disease blockbuster. ... The Anglo-Irish company claimed approval for first-in-class LFA-1 antagonist

  • Shire licences Parion dry eye drug in $535m deal Shire licences Parion dry eye drug in $535m deal

    All told the deal could be worth up to $535m for North Carolina biotech Parion, while Shire adds to the pipeline behind its recently-approved dry eye disease therapy Xiidra (lifitegrast). ... That is a different mechanism of action to current drugs

  • Shire launches dry eye drug Xiidra in US Shire launches dry eye drug Xiidra in US

    Shire's recently-approved dry eye disease drug Xiidra is now available in the US, throwing down a challenge to Allergan's rival therapy Restasis. ... That gives Xiidra a broader label than Restasis (cyclosporine) that analysts suggest could catapult it

  • FDA finally approves Shire’s potential blockbuster Xiidra FDA finally approves Shire’s potential blockbuster Xiidra

    Xiidra is tipped to be a $1bn product and is one of the stars of the Ireland-based manufacturer's pipeline. ... The only prescription eye drop indicated for the treatment of both signs and symptoms of this condition, Xiidra (lifitegrast ophthalmic

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    According to Bloomberg, the products Xiidra eyedrops for dry eye and Natpara for hypoparathyroidism may be considered as a source of funds to reduce the debt Takeda will incur in the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics